Article
A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Breast cancer research and treatment - 1 Jan 2015
Elster N, Cremona M, Morgan C, Toomey S, Carr A, O'Grady A, Hennessy B T, Eustace A J
Abstract excerpt
The PI3K pathway is a key mechanism of trastuzumab resistance, but early attempts to indirectly target this pathway with mTOR inhibitors have had limited success. We present the results of a preclinical study of the selective alpha/delta isoform dominant PI3K inhibitor BAY 80-6946 tested alone and in combination with HER2-targeted therapies in HER2-positive cell lines, including models with acquired resistance to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.